Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/18 | 1,254 | 1,302 | 1,247 | 1,297 | +33 | +2.6% | 145,500 |
| 2022/03/17 | 1,249 | 1,276 | 1,233 | 1,264 | +43 | +3.5% | 169,300 |
| 2022/03/16 | 1,195 | 1,235 | 1,179 | 1,221 | +41 | +3.5% | 185,700 |
| 2022/03/15 | 1,168 | 1,192 | 1,131 | 1,180 | -9 | -0.8% | 130,900 |
| 2022/03/14 | 1,174 | 1,207 | 1,144 | 1,189 | +6 | +0.5% | 181,800 |
| 2022/03/11 | 1,230 | 1,260 | 1,150 | 1,183 | -17 | -1.4% | 562,000 |
| 2022/03/10 | 1,202 | 1,230 | 1,104 | 1,200 | +28 | +2.4% | 703,100 |
| 2022/03/09 | 1,388 | 1,404 | 1,172 | 1,172 | -400 | -25.4% | 1,261,200 |
| 2022/03/08 | 1,568 | 1,636 | 1,547 | 1,572 | -4 | -0.3% | 193,200 |
| 2022/03/07 | 1,605 | 1,615 | 1,550 | 1,576 | -85 | -5.1% | 206,800 |
| 2022/03/04 | 1,730 | 1,730 | 1,622 | 1,661 | -98 | -5.6% | 299,500 |
| 2022/03/03 | 1,830 | 1,862 | 1,735 | 1,759 | -42 | -2.3% | 331,700 |
| 2022/03/02 | 1,759 | 1,827 | 1,729 | 1,801 | +2 | +0.1% | 217,800 |
| 2022/03/01 | 1,755 | 1,844 | 1,751 | 1,799 | +60 | +3.5% | 196,800 |
| 2022/02/28 | 1,622 | 1,755 | 1,619 | 1,739 | +52 | +3.1% | 242,200 |
| 2022/02/25 | 1,552 | 1,705 | 1,551 | 1,687 | +205 | +13.8% | 342,000 |
| 2022/02/24 | 1,572 | 1,623 | 1,449 | 1,482 | -115 | -7.2% | 440,900 |
| 2022/02/22 | 1,570 | 1,625 | 1,520 | 1,597 | -13 | -0.8% | 204,700 |
| 2022/02/21 | 1,560 | 1,642 | 1,560 | 1,610 | -20 | -1.2% | 181,800 |
| 2022/02/18 | 1,541 | 1,639 | 1,501 | 1,630 | +33 | +2.1% | 196,200 |
| 2022/02/17 | 1,734 | 1,734 | 1,496 | 1,597 | -168 | -9.5% | 538,700 |
| 2022/02/16 | 1,668 | 1,873 | 1,660 | 1,765 | +154 | +9.6% | 543,800 |
| 2022/02/15 | 1,551 | 1,629 | 1,503 | 1,611 | +69 | +4.5% | 244,100 |
| 2022/02/14 | 1,757 | 1,757 | 1,535 | 1,542 | -288 | -15.7% | 542,000 |
| 2022/02/10 | 1,847 | 1,923 | 1,798 | 1,830 | +43 | +2.4% | 268,700 |
| 2022/02/09 | 1,760 | 1,818 | 1,680 | 1,787 | +63 | +3.7% | 246,300 |
| 2022/02/08 | 1,746 | 1,785 | 1,691 | 1,724 | -61 | -3.4% | 322,700 |
| 2022/02/07 | 1,912 | 2,033 | 1,766 | 1,785 | -87 | -4.6% | 999,100 |
| 2022/02/04 | 1,940 | 1,968 | 1,812 | 1,872 | -108 | -5.5% | 1,053,500 |
| 2022/02/03 | 1,688 | 1,995 | 1,656 | 1,980 | +240 | +13.8% | 1,936,000 |
| 2022/02/02 | 1,467 | 1,790 | 1,425 | 1,740 | +250 | +16.8% | 2,629,100 |
| 2022/02/01 | 1,422 | 1,490 | 1,352 | 1,490 | +300 | +25.2% | 734,800 |
| 2022/01/31 | 1,161 | 1,214 | 1,161 | 1,190 | +29 | +2.5% | 90,400 |
| 2022/01/28 | 1,185 | 1,228 | 1,142 | 1,161 | -24 | -2% | 151,200 |
| 2022/01/27 | 1,247 | 1,264 | 1,167 | 1,185 | -62 | -5% | 138,700 |
| 2022/01/26 | 1,209 | 1,264 | 1,189 | 1,247 | +44 | +3.7% | 81,500 |
| 2022/01/25 | 1,291 | 1,351 | 1,183 | 1,203 | -118 | -8.9% | 270,700 |
| 2022/01/24 | 1,310 | 1,329 | 1,236 | 1,321 | -9 | -0.7% | 198,800 |
| 2022/01/21 | 1,353 | 1,360 | 1,319 | 1,330 | -50 | -3.6% | 100,300 |
| 2022/01/20 | 1,442 | 1,501 | 1,350 | 1,380 | -62 | -4.3% | 165,000 |
| 2022/01/19 | 1,427 | 1,479 | 1,414 | 1,442 | -1 | -0.1% | 116,900 |
| 2022/01/18 | 1,486 | 1,509 | 1,430 | 1,443 | -42 | -2.8% | 91,600 |
| 2022/01/17 | 1,547 | 1,554 | 1,474 | 1,485 | -35 | -2.3% | 76,800 |
| 2022/01/14 | 1,535 | 1,535 | 1,475 | 1,520 | -55 | -3.5% | 125,200 |
| 2022/01/13 | 1,543 | 1,575 | 1,490 | 1,575 | +11 | +0.7% | 66,500 |
| 2022/01/12 | 1,560 | 1,600 | 1,528 | 1,564 | +9 | +0.6% | 67,400 |
| 2022/01/11 | 1,453 | 1,569 | 1,429 | 1,555 | +119 | +8.3% | 138,800 |
| 2022/01/07 | 1,497 | 1,540 | 1,382 | 1,436 | -14 | -1% | 132,900 |
| 2022/01/06 | 1,471 | 1,496 | 1,438 | 1,450 | -46 | -3.1% | 98,400 |
| 2022/01/05 | 1,576 | 1,594 | 1,471 | 1,496 | -82 | -5.2% | 142,200 |
751～
800
件表示中 / 1584件
類似銘柄と比較する
現在ご覧いただいている「ＤＥＬＴＡ－Ｐ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＤＥＬＴＡ－Ｐ | 48,700円 | - | - | 0.00% | - | 15.09倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
| キッズバイオ | 11,500円 | - | - | 0.00% | - | 6.39倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞（ＳＨＥＤ）用いた再生医療に力 |
| カルナバイオ | 25,300円 | +13.5% | - | 0.00% | - | 1.95倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ＶＩＳ | 70,400円 | +306.2% | - | 0.00% | 27.18倍 | 2.07倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| 免疫生物 | 43,400円 | +13.4% | +44.0% | 0.00% | 18.80倍 | 3.03倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
市場注目の銘柄
チャート関連のコラム
